CYCLACEL PHARMACEUTICALS INC (CYCC)

US23254L8019 - Common Stock

2.2999  +0.51 (+28.49%)

After market: 2.57 +0.27 (+11.74%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

CYCLACEL PHARMACEUTICALS INC

NASDAQ:CYCC (4/24/2024, 7:00:01 PM)

After market: 2.57 +0.27 (+11.74%)

2.2999

+0.51 (+28.49%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap3.04M
Shares
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

CYCC Daily chart

Company Profile

Cyclacel Pharmaceuticals Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Berkeley Heights, New Jersey. Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The firm is focused on developing cancer medicines based on cell cycle, transcriptional regulation and mitosis control biology. The transcriptional regulation program is evaluating fadraciclib, a Cyclin-dependent kinase 9 (CDK9) inhibitor, in solid tumors and hematological malignancies. The anti-mitotic program is evaluating plogosertib, a PLK1 inhibitor, in solid tumors and hematological malignancies. The firm's Mitosis Regulation program includes Plogosertib, which is a novel, small molecule, selective and potent Polo-like kinase 1 (PLK1) inhibitor. Plogosertib has demonstrated potent and selective target inhibition (PLK1 IC50 approximately 3 nM) and impressive efficacy in human tumor xenografts at non-toxic doses. Its translational biology program supports the development of plogosertib in acute leukemias and solid tumors.

Company Info

CYCLACEL PHARMACEUTICALS INC

200 Connell Dr Ste 1500

Berkeley Heights NEW JERSEY 07922

P: 19085177330

CEO: Spiro Rombotis

Employees: 0

Website: https://cyclacel.com/

CYCC News

News Image24 days ago - CyclacelCyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib’s Potential as a Precision Medicine for Cancer
News Image24 days ago - CyclacelCyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib’s Potential as a Precision Medicine for Cancer

- New clinical, PK and PD data from novel CDK2/9 inhibitor fadraciclib monotherapy studies support ongoing development program in patients with solid...

News Imagea month ago - InvestorPlaceCYCC Stock Earnings: Cyclacel Pharmaceuticals Misses EPS for Q4 2023

CYCC stock results show that Cyclacel Pharmaceuticals missed analyst estimates for earnings per share the fourth quarter of 2023.

News Imagea month ago - BusinessInsiderCYCC Stock Earnings: Cyclacel Pharmaceuticals Misses EPS for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Cyclacel Pharmaceuticals (NASDAQ:CYCC) just reported results for the fourth qua...

News Imagea month ago - CyclacelCyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
News Imagea month ago - CyclacelCyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

– On Track to Start Oral Fadraciclib Phase 2 Proof of Concept in 1H 2024 – – Expect to Report Final Data from Fadraciclib 065-101 Dose Escalation – ...

CYCC Twits

Here you can normally see the latest stock twits on CYCC, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example